Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dina Lev

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Cancer Research|July 28, 2012
INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcomaJinming Yang, Sara Kantrow, Jiqing Sai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Optimizing treatment of desmoid tumorsDina Lev, Dhanasekaran Kotilingam, Caimiao Wei, et al.
Plos One|November 30, 2017
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlatesGonzalo Lopez, Danielle Braggio, Abeba Zewdu, et al.
Annals of Surgical Oncology|May 27, 2011
Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasisMarkus P Ghadimi, Tariq Al-Zaid, John Madewell, et al.
Oncogene|July 12, 2020
β-catenin S45F mutation results in apoptotic resistanceDanielle Braggio, Abeba Zewdu, Priya Londhe, et al.
Oncotarget|September 20, 2014
Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcomaJu-Ae Hwang, Heung-Mo Yang, Doo-Pyo Hong, et al.
Cancer|April 30, 2009
Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registryDan G Blazer, Alexander J Lazar, Yan Xing, et al.
Molecular Cancer Therapeutics|May 22, 2007
Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulationJonathan A F Hannay, Juehui Liu, Quan-Sheng Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Eric D Young, Roman Belousov, et al.
Molecular Cancer Therapeutics|August 1, 2012
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Gonzalo Lopez, Keila E Torres, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Cancer Research|July 28, 2012
INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcomaJinming Yang, Sara Kantrow, Jiqing Sai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Optimizing treatment of desmoid tumorsDina Lev, Dhanasekaran Kotilingam, Caimiao Wei, et al.
Plos One|November 30, 2017
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlatesGonzalo Lopez, Danielle Braggio, Abeba Zewdu, et al.
Annals of Surgical Oncology|May 27, 2011
Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasisMarkus P Ghadimi, Tariq Al-Zaid, John Madewell, et al.
Oncogene|July 12, 2020
β-catenin S45F mutation results in apoptotic resistanceDanielle Braggio, Abeba Zewdu, Priya Londhe, et al.
Oncotarget|September 20, 2014
Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcomaJu-Ae Hwang, Heung-Mo Yang, Doo-Pyo Hong, et al.
Cancer|April 30, 2009
Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registryDan G Blazer, Alexander J Lazar, Yan Xing, et al.
Molecular Cancer Therapeutics|May 22, 2007
Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulationJonathan A F Hannay, Juehui Liu, Quan-Sheng Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2012
Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Eric D Young, Roman Belousov, et al.
Molecular Cancer Therapeutics|August 1, 2012
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumorsMarkus P Ghadimi, Gonzalo Lopez, Keila E Torres, et al.
Pageof 11